LinusBio is a patient-centric, precision exposome medicine company, originating from the world’s leading exposome laboratory at Mount Sinai Health System. LinusBio has developed a technology platform that builds on breakthroughs in exposome sequencing, utilizing a single stand of hair. LinusBio’ early autism diagnostic aid, StrandDx-ASD has been granted an FDA Breakthrough Designation.
The Company’s program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology.
The Company’s program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2021
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
StrandDx-ASD
Development Phase of Primary Product:
Other/Not Applicable
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
